CN103864813A - 一种合成六氢呋喃并[2,3-b]呋喃-3-醇及其对映体的方法 - Google Patents
一种合成六氢呋喃并[2,3-b]呋喃-3-醇及其对映体的方法 Download PDFInfo
- Publication number
- CN103864813A CN103864813A CN201210552770.8A CN201210552770A CN103864813A CN 103864813 A CN103864813 A CN 103864813A CN 201210552770 A CN201210552770 A CN 201210552770A CN 103864813 A CN103864813 A CN 103864813A
- Authority
- CN
- China
- Prior art keywords
- compound
- sodium
- acid
- furan
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010189 synthetic method Methods 0.000 title abstract description 9
- RCDXYCHYMULCDZ-UHFFFAOYSA-N 2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-ol Chemical compound O1CCC2C(O)COC21 RCDXYCHYMULCDZ-UHFFFAOYSA-N 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims abstract description 10
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 28
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 19
- 125000002541 furyl group Chemical group 0.000 claims description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000006722 reduction reaction Methods 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 3
- 239000012279 sodium borohydride Substances 0.000 claims description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 3
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 2
- PZHIWRCQKBBTOW-UHFFFAOYSA-N 1-ethoxybutane Chemical compound CCCCOCC PZHIWRCQKBBTOW-UHFFFAOYSA-N 0.000 claims description 2
- JUSXLWAFYVKNLT-UHFFFAOYSA-N 2-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1Br JUSXLWAFYVKNLT-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- BDFJWKALVSRGSR-UHFFFAOYSA-N butan-1-ol;sodium Chemical compound [Na].CCCCO BDFJWKALVSRGSR-UHFFFAOYSA-N 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 2
- 229960003424 phenylacetic acid Drugs 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- LMHHRCOWPQNFTF-UHFFFAOYSA-N s-propan-2-yl azepane-1-carbothioate Chemical compound CC(C)SC(=O)N1CCCCCC1 LMHHRCOWPQNFTF-UHFFFAOYSA-N 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 abstract description 9
- 229960005107 darunavir Drugs 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- RCDXYCHYMULCDZ-HCWXCVPCSA-N (3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-ol Chemical compound O1CC[C@H]2[C@@H](O)CO[C@H]21 RCDXYCHYMULCDZ-HCWXCVPCSA-N 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- 238000006243 chemical reaction Methods 0.000 description 22
- 239000000243 solution Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- -1 nitro methyl Chemical group 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019093 NaOCl Inorganic materials 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 150000002240 furans Chemical class 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 3
- KQUNZICWZYLJTJ-UHFFFAOYSA-N 3-(2-phenylmethoxyacetyl)oxolan-2-one Chemical compound C1COC(=O)C1C(=O)COCC1=CC=CC=C1 KQUNZICWZYLJTJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 101710168592 Gag-Pol polyprotein Proteins 0.000 description 1
- 229910052769 Ytterbium Inorganic materials 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- VJLOFJZWUDZJBX-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;chloride Chemical compound [Cl-].OCC[NH2+]CCO VJLOFJZWUDZJBX-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- ZRSDQBKGDNPFLT-UHFFFAOYSA-N ethanol;oxolane Chemical compound CCO.C1CCOC1 ZRSDQBKGDNPFLT-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- RNWIJLZQJSGBCU-UHFFFAOYSA-N furan-3-ol Chemical compound OC=1C=COC=1 RNWIJLZQJSGBCU-UHFFFAOYSA-N 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940068586 prezista Drugs 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210552770.8A CN103864813B (zh) | 2012-12-18 | 2012-12-18 | 一种合成六氢呋喃并[2,3‑b]呋喃‑3‑醇及其对映体的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210552770.8A CN103864813B (zh) | 2012-12-18 | 2012-12-18 | 一种合成六氢呋喃并[2,3‑b]呋喃‑3‑醇及其对映体的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103864813A true CN103864813A (zh) | 2014-06-18 |
CN103864813B CN103864813B (zh) | 2017-02-22 |
Family
ID=50903880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210552770.8A Active CN103864813B (zh) | 2012-12-18 | 2012-12-18 | 一种合成六氢呋喃并[2,3‑b]呋喃‑3‑醇及其对映体的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103864813B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017041228A1 (zh) * | 2015-09-08 | 2017-03-16 | 浙江九洲药业股份有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
CN107043385A (zh) * | 2016-02-05 | 2017-08-15 | 成都博腾药业有限公司 | 一种制备地瑞那韦中间体的方法 |
CN107344944A (zh) * | 2016-05-07 | 2017-11-14 | 成都博腾药业有限公司 | 一种制备地瑞那韦中间体的方法 |
WO2019174176A1 (zh) * | 2018-03-16 | 2019-09-19 | 江苏瑞科医药科技有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
CN112300186A (zh) * | 2019-08-01 | 2021-02-02 | 浙江九洲药业股份有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060905A2 (en) * | 2000-10-24 | 2002-08-08 | Glaxo Group Ltd | METHOD FOR PREPARING HIV PROTEASE INHIBITOR INTERMEDIATES |
WO2004002975A1 (en) * | 2002-06-27 | 2004-01-08 | Smithkline Beecham Corporation | PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO[2,3-b]FURAN-3-OL |
CN1553915A (zh) * | 2001-09-10 | 2004-12-08 | ̩���ؿ�ҩƷ����˾ | 制备六氢-呋喃并[2,3-b]呋喃-3-醇的方法 |
CN1753898A (zh) * | 2002-12-27 | 2006-03-29 | 住友化学株式会社 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
CN1938316A (zh) * | 2004-03-31 | 2007-03-28 | 泰博特克药品有限公司 | 制备(3R,3aS,6aR)六氢-呋喃并[2,3-b]呋喃-3-醇的方法 |
CN102432621A (zh) * | 2006-11-09 | 2012-05-02 | 泰博特克药品有限公司 | 六氢呋喃并[2,3-b]呋喃-3-醇的制备方法 |
-
2012
- 2012-12-18 CN CN201210552770.8A patent/CN103864813B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060905A2 (en) * | 2000-10-24 | 2002-08-08 | Glaxo Group Ltd | METHOD FOR PREPARING HIV PROTEASE INHIBITOR INTERMEDIATES |
CN1553915A (zh) * | 2001-09-10 | 2004-12-08 | ̩���ؿ�ҩƷ����˾ | 制备六氢-呋喃并[2,3-b]呋喃-3-醇的方法 |
WO2004002975A1 (en) * | 2002-06-27 | 2004-01-08 | Smithkline Beecham Corporation | PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO[2,3-b]FURAN-3-OL |
CN1753898A (zh) * | 2002-12-27 | 2006-03-29 | 住友化学株式会社 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
CN1938316A (zh) * | 2004-03-31 | 2007-03-28 | 泰博特克药品有限公司 | 制备(3R,3aS,6aR)六氢-呋喃并[2,3-b]呋喃-3-醇的方法 |
CN102432621A (zh) * | 2006-11-09 | 2012-05-02 | 泰博特克药品有限公司 | 六氢呋喃并[2,3-b]呋喃-3-醇的制备方法 |
Non-Patent Citations (1)
Title |
---|
WILL L. CANOY,等: "Efficient Synthesis of (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol from Glycolaldehyde", 《ORG. LETT.》 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017041228A1 (zh) * | 2015-09-08 | 2017-03-16 | 浙江九洲药业股份有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
CN107043385A (zh) * | 2016-02-05 | 2017-08-15 | 成都博腾药业有限公司 | 一种制备地瑞那韦中间体的方法 |
CN107043385B (zh) * | 2016-02-05 | 2019-07-09 | 成都博腾药业有限公司 | 一种制备地瑞那韦中间体的方法 |
CN107344944A (zh) * | 2016-05-07 | 2017-11-14 | 成都博腾药业有限公司 | 一种制备地瑞那韦中间体的方法 |
CN107344944B (zh) * | 2016-05-07 | 2021-03-05 | 成都博腾药业有限公司 | 一种制备地瑞那韦中间体的方法 |
WO2019174176A1 (zh) * | 2018-03-16 | 2019-09-19 | 江苏瑞科医药科技有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
CN110272398A (zh) * | 2018-03-16 | 2019-09-24 | 江苏瑞科医药科技有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
US11535601B2 (en) | 2018-03-16 | 2022-12-27 | Jiangsu Ruike Medical Science And Technology Co., Ltd. | Method for preparing hexahydrofuro-furanol derivative, intermediate thereof and preparation method thereof |
CN112300186A (zh) * | 2019-08-01 | 2021-02-02 | 浙江九洲药业股份有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
WO2021018085A1 (zh) * | 2019-08-01 | 2021-02-04 | 浙江九洲药业股份有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
CN112300186B (zh) * | 2019-08-01 | 2024-04-30 | 浙江九洲药业股份有限公司 | 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103864813B (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103864813A (zh) | 一种合成六氢呋喃并[2,3-b]呋喃-3-醇及其对映体的方法 | |
CN107129462B (zh) | 一种天然产物(±)-一枝蒿碱g的全合成及对映异构体的拆分方法 | |
CN103896886A (zh) | 一种达鲁那韦中间体及其制备方法和应用 | |
CN104520262A (zh) | 六氢呋喃并呋喃醇衍生物的制造方法 | |
CN108148070B (zh) | 一种呋喃酮并异喹啉酮类化合物的合成方法 | |
WO2008015977A1 (en) | PROCESS FOR PRODUCTION OF (±)-3a,6,6,9a– TETRAMETHYLDECAHYDRONAPHTHO[2,1-b]FURAN-2(1H)-ONE | |
CN112154140B (zh) | 化合物及其在合成布瓦西坦(Brivaracetam)原料药中的用途 | |
CN110878099B (zh) | 一种吡咯[1,2,α]吲哚生物碱衍生物的制备方法 | |
CN105348241B (zh) | 一种硫酸沃拉帕沙中间体的合成方法 | |
CN101215291B (zh) | (+)-生物素及其衍生物的合成方法 | |
CN105820174A (zh) | 一种多取代噻吩并吲哚衍生物的制备方法 | |
CN114293210B (zh) | 一种利用微反应装置连续电合成苯并吡喃-4-酮的方法 | |
CN106905358B (zh) | 一种制备维生素d3类似物中间体的方法 | |
CN109879800B (zh) | 一种贝他斯汀药物中间体的制备工艺 | |
CN112010882B (zh) | 立体选择性制备3,5-双取代环己烯类化合物的方法及应用 | |
JP4156655B2 (ja) | (±)−3a、6、6、9a−テトラメチルデカヒドロナフト[2、1−b]フラン−2(1H)−オン類の製造方法 | |
CN108299173B (zh) | 一种地佐辛关键中间体的不对称合成方法 | |
KR102587674B1 (ko) | 트레프로스티닐의 제조방법 | |
CN102079720B (zh) | 一种制备1-苄基-4-哌啶甲醛的方法 | |
CN106957288A (zh) | 一种医药中间体及其制备方法 | |
CN103450182B (zh) | 一种瑞他帕林的制备和纯化方法 | |
CN113372274B (zh) | 一种伊伐布雷定的制备方法 | |
CN110016030B (zh) | 一种5-氟-1H-吡咯-[2,3-b]吡啶-4-甲醛的制备方法 | |
CN108299445B (zh) | 一种1,5-氮杂螺[2,4]庚烷的合成方法 | |
CN106432234A (zh) | 一种1‑苯乙酰基‑β‑咔啉类衍生物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190506 Address after: Room 338, Building 2, 456 Liangxin Road, Laogang Town, Pudong New Area, Shanghai, 2013 Co-patentee after: YANCHENG DESANO PHARMACEUTICAL Co.,Ltd. Patentee after: SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd. Address before: Room 338, Building 2, 456 Liangxin Road, Laogang Town, Pudong New Area, Shanghai, 2013 Patentee before: SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240228 Address after: 331299 Zhangshu salt chemical industrial base, Yichun City, Jiangxi Province Patentee after: Jiangxi desino Pharmaceutical Co.,Ltd. Country or region after: China Patentee after: SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd. Patentee after: YANCHENG DESANO PHARMACEUTICAL Co.,Ltd. Address before: Room 338, Building 2, 456 Liangxin Road, Laogang Town, Pudong New Area, Shanghai, 2013 Patentee before: SHANGHAI DESANO CHEMICAL PHARMACEUTICAL Co.,Ltd. Country or region before: China Patentee before: YANCHENG DESANO PHARMACEUTICAL Co.,Ltd. |